686 related articles for article (PubMed ID: 27502297)
1. β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis.
Kolbinger F; Loesche C; Valentin MA; Jiang X; Cheng Y; Jarvis P; Peters T; Calonder C; Bruin G; Polus F; Aigner B; Lee DM; Bodenlenz M; Sinner F; Pieber TR; Patel DD
J Allergy Clin Immunol; 2017 Mar; 139(3):923-932.e8. PubMed ID: 27502297
[TBL] [Abstract][Full Text] [Related]
2. Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab.
Morita A; Tani Y; Matsumoto K; Yamaguchi M; Teshima R; Ohtsuki M
J Dermatol; 2020 May; 47(5):452-457. PubMed ID: 32173900
[TBL] [Abstract][Full Text] [Related]
3. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.
Krueger JG; Wharton KA; Schlitt T; Suprun M; Torene RI; Jiang X; Wang CQ; Fuentes-Duculan J; Hartmann N; Peters T; Koroleva I; Hillenbrand R; Letzkus M; Yu X; Li Y; Glueck A; Hasselberg A; Flannery B; Suárez-Fariñas M; Hueber W
J Allergy Clin Immunol; 2019 Sep; 144(3):750-763. PubMed ID: 31129129
[TBL] [Abstract][Full Text] [Related]
4. Effect of IL-17A blockade with secukinumab in autoimmune diseases.
Patel DD; Lee DM; Kolbinger F; Antoni C
Ann Rheum Dis; 2013 Apr; 72 Suppl 2():ii116-23. PubMed ID: 23253932
[TBL] [Abstract][Full Text] [Related]
5. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
Sofen H; Smith S; Matheson RT; Leonardi CL; Calderon C; Brodmerkel C; Li K; Campbell K; Marciniak SJ; Wasfi Y; Wang Y; Szapary P; Krueger JG
J Allergy Clin Immunol; 2014 Apr; 133(4):1032-40. PubMed ID: 24679469
[TBL] [Abstract][Full Text] [Related]
6. Alteration of serum thymus and activation-regulated chemokine level during biologic therapy for psoriasis: Possibility as a marker reflecting favorable response to anti-interleukin-17A agents.
Shibuya T; Honma M; Iinuma S; Iwasaki T; Takahashi H; Ishida-Yamamoto A
J Dermatol; 2018 Jun; 45(6):710-714. PubMed ID: 29655215
[TBL] [Abstract][Full Text] [Related]
7. Psoriasis: rationale for targeting interleukin-17.
Girolomoni G; Mrowietz U; Paul C
Br J Dermatol; 2012 Oct; 167(4):717-24. PubMed ID: 22716185
[TBL] [Abstract][Full Text] [Related]
8. Ultra-Sensitive Measurement of IL-17A and IL-17F in Psoriasis Patient Serum and Skin.
Soderstrom C; Berstein G; Zhang W; Valdez H; Fitz L; Kuhn M; Fraser S
AAPS J; 2017 Jul; 19(4):1218-1222. PubMed ID: 28534291
[TBL] [Abstract][Full Text] [Related]
9. IL-17 for therapy.
Kurschus FC; Moos S
J Dermatol Sci; 2017 Sep; 87(3):221-227. PubMed ID: 28633806
[TBL] [Abstract][Full Text] [Related]
10. Anthralin modulates the expression pattern of cytokeratins and antimicrobial peptides by psoriatic keratinocytes.
Holstein J; Fehrenbacher B; Brück J; Müller-Hermelink E; Schäfer I; Carevic M; Schittek B; Schaller M; Ghoreschi K; Eberle FC
J Dermatol Sci; 2017 Sep; 87(3):236-245. PubMed ID: 28673488
[TBL] [Abstract][Full Text] [Related]
11. IκBζ is a key player in the antipsoriatic effects of secukinumab.
Bertelsen T; Ljungberg C; Litman T; Huppertz C; Hennze R; Rønholt K; Iversen L; Johansen C
J Allergy Clin Immunol; 2020 Jan; 145(1):379-390. PubMed ID: 31622687
[TBL] [Abstract][Full Text] [Related]
12. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis.
Hueber W; Patel DD; Dryja T; Wright AM; Koroleva I; Bruin G; Antoni C; Draelos Z; Gold MH; ; Durez P; Tak PP; Gomez-Reino JJ; ; Foster CS; Kim RY; Samson CM; Falk NS; Chu DS; Callanan D; Nguyen QD; ; Rose K; Haider A; Di Padova F
Sci Transl Med; 2010 Oct; 2(52):52ra72. PubMed ID: 20926833
[TBL] [Abstract][Full Text] [Related]
13. Galectin-7 downregulation in lesional keratinocytes contributes to enhanced IL-17A signaling and skin pathology in psoriasis.
Chen HL; Lo CH; Huang CC; Lu MP; Hu PY; Chen CS; Chueh DY; Chen P; Lin TN; Lo YH; Hsiao YP; Hsu DK; Liu FT
J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33055419
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin.
Johansen C; Usher PA; Kjellerup RB; Lundsgaard D; Iversen L; Kragballe K
Br J Dermatol; 2009 Feb; 160(2):319-24. PubMed ID: 19016708
[TBL] [Abstract][Full Text] [Related]
15. IL-17 Blockade in Psoriasis.
Burkett PR; Kuchroo VK
Cell; 2016 Dec; 167(7):1669. PubMed ID: 27984714
[TBL] [Abstract][Full Text] [Related]
16. Secukinumab for rheumatology: development and its potential place in therapy.
Koenders MI; van den Berg WB
Drug Des Devel Ther; 2016; 10():2069-80. PubMed ID: 27445458
[TBL] [Abstract][Full Text] [Related]
17. Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.
Gottlieb AB; Langley RG; Philipp S; Sigurgeirsson B; Blauvelt A; Martin R; Papavassilis C; Mpofu S
J Drugs Dermatol; 2015 Aug; 14(8):821-33. PubMed ID: 26267726
[TBL] [Abstract][Full Text] [Related]
18. Safety of secukinumab in the treatment of psoriasis.
Blauvelt A
Expert Opin Drug Saf; 2016 Oct; 15(10):1413-20. PubMed ID: 27545070
[TBL] [Abstract][Full Text] [Related]
19. Involvement of IL-17F via the induction of IL-6 in psoriasis.
Fujishima S; Watanabe H; Kawaguchi M; Suzuki T; Matsukura S; Homma T; Howell BG; Hizawa N; Mitsuya T; Huang SK; Iijima M
Arch Dermatol Res; 2010 Sep; 302(7):499-505. PubMed ID: 20148256
[TBL] [Abstract][Full Text] [Related]
20. A novel role of IL-17A in contributing to the impaired suppressive function of Tregs in psoriasis.
Liu Y; Zhang C; Li B; Yu C; Bai X; Xiao C; Wang L; Dang E; Yang L; Wang G
J Dermatol Sci; 2021 Feb; 101(2):84-92. PubMed ID: 33334656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
